Key Biosimilars Events of April 2025

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   Henlius Collaborates with Sandoz for the Commercialization of HLX13. Our team at PharmaShots…

ByDipanshu DixitMay 6, 2025

INSIGHTS+

Key Biosimilars Events of March 2025

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   Bio-Thera Collaborates with Dr. Reddy’s for the Commercialization of BAT2206 & BAT2506…

ByDipanshu DixitApril 8, 2025

News

Alnylam Pharmaceuticals and Sanofi Report the US FDA’s Approval of Qfitlia (Fitusiran) to Treat Hemophilia A or B

Shots:The US FDA has approved Qfitlia to treat routine prophylaxis and prevent or reduce the frequency of bleeding episodes in pts. (age≥ 12yrs.) with hemophilia A or B, with or without factor VIII or IX inhibitors. Regulatory submissions have been completed in China & BrazilQfitlia published clinical data in the NEJM in 2017, showing…

ByRidhi RastogiApril 1, 2025

News

Bio-Thera Collaborates with Dr. Reddy’s for the Commercialization of BAT2206 (Biosimilar, Stelara) & BAT2506 (Biosimilar, Simponi) Across the Southeast Asia

Shots: Bio-Thera and Dr. Reddy’s have entered into an exclusive commercialization and license agreement for BAT2506, a biosimilar version of Simponi (golimumab) & BAT2206, a biosimilar version of Stelara (ustekinumab) As per the agreement, Bio-Thera will handle the development, manufacturing, and supply of BAT2206 & BAT2506, while Dr. Reddy’s will manage regulatory approvals &…

ByDipanshu DixitMarch 28, 2025

News

Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US

Shots:Biocon Biologics has entered into strategic collaboration agreement with Civica to extend access & affordability of Insulin Aspart in the US As per the deal, Biocon will supply Insulin Aspart drug substance to Civica, which will manufacture prefilled pens & vials of insulin at its Petersburg, Virginia facility. Civica will commercialize it in the US…

ByRidhi RastogiMarch 7, 2025

INSIGHTS+

Key Biosimilars Events of February 2025

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   A major highlight was the Samsung Bioepis & Teva Partners to Commercialize…

ByDipanshu DixitMarch 4, 2025

INSIGHTS+

Key Biosimilars Events of January 2025

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   A major highlight was the Samsung Bioepis & Teva Partners to Commercialize Epysqli in…

ByDipanshu DixitFebruary 4, 2025

VIEWPOINTS

Intelligent Automation and Beyond: Dale Curtis Jr from Astrix in an Enlightening Conversation with PharmaShots

Shots: The biopharma industry faces several challenges, including digital transformation, regulatory compliance, and managing large volumes of data Intelligent automation plays a vital role in drug discovery, clinical trials, manufacturing, and commercialization, helping optimize operations and better meet customer needs Astrix CEO Dale Curtis Jr. discusses the role of AI and machine learning in global…

BySaurabh ChaubeyJanuary 31, 2025

TOP 20

Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Shots: Sticking to M&A and licensing agreements can be really challenging, especially when dealing with stringent antitrust laws and evolving regulatory challenges. In such adverse scenarios, the rational and right step seems to be nullifying the existing deals.In 2023, the termination of the deal between Janssen and Arrowhead remained the talk of the town…

ByPrince GiriApril 18, 2024

THOUGHTSPOT

Competitive Intelligence: A Substantial Advantage for the Pharmaceutical Sector

“The supreme art of war is to subdue the enemy without fighting” – Sun Zhu, Competitive Intelligence benefits your organization gather and analyzing information related to your competitor’s business models. This deep analysis helps your organization reduce the strategic risks and increase revenue opportunities by attaining deep insights into how the market has changed and…

BySaurabh ChaubeyOctober 11, 2022

Key Biosimilars Events of April 2025

Key Biosimilars Events of March 2025

Alnylam Pharmaceuticals and Sanofi Report the US FDA’s Approval of Qfitlia (Fitusiran) to Treat Hemophilia A or B

Bio-Thera Collaborates with Dr. Reddy’s for the Commercialization of BAT2206 (Biosimilar, Stelara) & BAT2506 (Biosimilar, Simponi) Across the Southeast Asia

Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US

Key Biosimilars Events of February 2025

Key Biosimilars Events of January 2025

Intelligent Automation and Beyond: Dale Curtis Jr from Astrix in an Enlightening Conversation with PharmaShots

Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Competitive Intelligence: A Substantial Advantage for the Pharmaceutical Sector

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter